PMID- 32545941
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211213
IS  - 2784-8450 (Electronic)
IS  - 2784-8671 (Linking)
VI  - 156
IP  - 4
DP  - 2021 Aug
TI  - Clinical and immunological profile of patients with dipeptidyl peptidase-4 
      inhibitor-associated bullous pemphigoid.
PG  - 455-459
LID - 10.23736/S2784-8671.20.06562-1 [doi]
AB  - BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering disease caused by 
      antibodies against the hemidesmosomal BP180 and/or BP230 proteins. There is an 
      increasing evidence that the use of dipeptidyl peptidase-4 inhibitors, also known 
      as gliptins, increases the risk for BP. The gliptins more frequently associated 
      with BP are vildagliptin and sitagliptin. Clinical, immunological and 
      pathological features of gliptin-associated BP have been reported to be distinct, 
      compared to classic BP. METHODS: In this study, 15 gliptin-associated BP (g-BP) 
      cases have been compared with 16 consecutive idiopathic BP (i-BP) to clarify 
      whether g-BP has distinctive clinical and immunopathological characteristics. 
      Comorbidities, concomitant treatments, latency of the onset of the disease and 
      the time to achieve the remission were also considered. RESULTS: The mean latency 
      from drug intake to g-BP appearance was 9.4 months (median 10, inter-quartile 
      range [IQR] 6-12). There were no differences in sex and age prevalence between 
      the two groups (g-BP median age 77 years, IQR: 70-84; i-BP: 81 years, IQR: 
      72-86). There were no differences as far clinical presentation including disease 
      severity, lesions types (urticarial and bullous) or mucosal involvement between 
      g-BP and i-BP cases. The median antibody anti-BP180 and anti-BP230 titers was 
      also similar between the two groups with 29.1 UI/mL (IQR: 12.9-65.3) and 11.8 
      UI/mL (IQR: 1.7-26.3), respectively. Gliptins were withdrawn in ten out of 15 
      patients and remission was achieved with systemic corticosteroids (0.3-0.7 mg/Kg 
      daily) alone or in association with doxycycline (100-200 mg daily) within a mean 
      of 8 months. CONCLUSIONS: A non-inflammatory phenotype with less erythema, fewer 
      urticarial lesions and fewer eosinophils in skin lesions has been associated with 
      gliptins in selected Japanese BP populations. As reported in European studies, no 
      significant differences among the considered variables in the g-BP and i-BP cases 
      have been found in our study.
FAU - Bellinato, Francesco
AU  - Bellinato F
AD  - Section of Dermatology and Venereology, Department of Medicine, University of 
      Verona, Verona, Italy - francesco.bellinato@gmail.com.
FAU - Maurelli, Martina
AU  - Maurelli M
AD  - Section of Dermatology and Venereology, Department of Medicine, University of 
      Verona, Verona, Italy.
FAU - Schena, Donatella
AU  - Schena D
AD  - Section of Dermatology and Venereology, Department of Medicine, University of 
      Verona, Verona, Italy.
FAU - Gisondi, Paolo
AU  - Gisondi P
AD  - Section of Dermatology and Venereology, Department of Medicine, University of 
      Verona, Verona, Italy.
FAU - Girolomoni, Giampiero
AU  - Girolomoni G
AD  - Section of Dermatology and Venereology, Department of Medicine, University of 
      Verona, Verona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - Italy
TA  - Ital J Dermatol Venerol
JT  - Italian journal of dermatology and venereology
JID - 101778002
RN  - 0 (Autoantigens)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
RN  - I6B4B2U96P (Vildagliptin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Autoantigens
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
MH  - Humans
MH  - *Pemphigoid, Bullous/chemically induced
MH  - Vildagliptin
EDAT- 2020/06/18 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/06/18 06:00 [entrez]
AID - S0392-0488.20.06562-1 [pii]
AID - 10.23736/S2784-8671.20.06562-1 [doi]
PST - ppublish
SO  - Ital J Dermatol Venerol. 2021 Aug;156(4):455-459. doi: 
      10.23736/S2784-8671.20.06562-1. Epub 2020 Jun 15.